[go: up one dir, main page]

RU2018125290A3 - - Google Patents

Download PDF

Info

Publication number
RU2018125290A3
RU2018125290A3 RU2018125290A RU2018125290A RU2018125290A3 RU 2018125290 A3 RU2018125290 A3 RU 2018125290A3 RU 2018125290 A RU2018125290 A RU 2018125290A RU 2018125290 A RU2018125290 A RU 2018125290A RU 2018125290 A3 RU2018125290 A3 RU 2018125290A3
Authority
RU
Russia
Application number
RU2018125290A
Other versions
RU2018125290A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018125290A publication Critical patent/RU2018125290A/ru
Publication of RU2018125290A3 publication Critical patent/RU2018125290A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2018125290A 2016-01-12 2017-01-11 Фармацевтические композиции и их применение для лечения пигментного ретинита RU2018125290A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102016000001989 2016-01-12
ITUB2016A009937A ITUB20169937A1 (it) 2016-01-12 2016-01-12 Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
PCT/EP2017/050497 WO2017121766A1 (en) 2016-01-12 2017-01-11 Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa

Publications (2)

Publication Number Publication Date
RU2018125290A RU2018125290A (ru) 2020-02-13
RU2018125290A3 true RU2018125290A3 (ru) 2020-06-22

Family

ID=55806719

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018125290A RU2018125290A (ru) 2016-01-12 2017-01-11 Фармацевтические композиции и их применение для лечения пигментного ретинита

Country Status (13)

Country Link
US (1) US20180353565A1 (ru)
EP (1) EP3402504A1 (ru)
JP (1) JP2019504006A (ru)
KR (1) KR20180100574A (ru)
CN (1) CN108463237A (ru)
AU (1) AU2017206626A1 (ru)
CA (1) CA3011077A1 (ru)
HK (1) HK1259382A1 (ru)
IL (1) IL260517B (ru)
IT (1) ITUB20169937A1 (ru)
RU (1) RU2018125290A (ru)
WO (1) WO2017121766A1 (ru)
ZA (1) ZA201804589B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245012A1 (ja) * 2018-06-21 2019-12-26 第一三共株式会社 網膜色素変性症治療用ペプチド
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236157A1 (en) 1995-11-29 1997-06-05 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product
DE69739190D1 (de) 1996-10-28 2009-02-12 Senju Pharma Co Arzneimittel zur behandlung von oculären kreislauferkrankungen
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
WO2003007979A1 (en) 2001-07-18 2003-01-30 Board Of Regents, The University Of Texas System An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
JP4953040B2 (ja) 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
US20080317885A1 (en) 2005-07-15 2008-12-25 Baker Donald J Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
ITMI20061607A1 (it) * 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2009111169A2 (en) 2008-02-29 2009-09-11 Bausch & Lomb Incorporated Compositions comprising pkc-delta modulators and methods for ocular neuroprotection
US20120108654A1 (en) 2008-06-30 2012-05-03 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
JP2012062258A (ja) 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
KR102110200B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 산화성 망막 질환
US20150328337A1 (en) 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
WO2014100433A1 (en) * 2012-12-19 2014-06-26 Brown University Methods for treatment of microcephaly associated autism disorders
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
EP3331897B1 (en) * 2015-08-05 2021-03-24 Allergan, Inc. Phenyl urea analogs as formyl peptide receptor 1 (fpr1) selective agonists

Also Published As

Publication number Publication date
WO2017121766A1 (en) 2017-07-20
US20180353565A1 (en) 2018-12-13
IL260517B (en) 2020-04-30
CN108463237A (zh) 2018-08-28
EP3402504A1 (en) 2018-11-21
KR20180100574A (ko) 2018-09-11
AU2017206626A1 (en) 2018-07-26
HK1259382A1 (zh) 2019-11-29
ZA201804589B (en) 2019-09-25
JP2019504006A (ja) 2019-02-14
CA3011077A1 (en) 2017-07-20
RU2018125290A (ru) 2020-02-13
ITUB20169937A1 (it) 2017-07-12

Similar Documents

Publication Publication Date Title
BR112019009389A2 (ru)
BR112019009192A2 (ru)
RU2018125290A3 (ru)
BR112019006736A2 (ru)
CN303538746S (ru)
CN303742605S (ru)
CN303537566S (ru)
CN303537519S (ru)
CN303537427S (ru)
CN303537358S (ru)
CN303719093S (ru)
CN303716257S (ru)
CN303699730S (ru)
CN303689419S (ru)
CN303537271S (ru)
CN303655115S (ru)
CN303651746S (ru)
CN303640523S (ru)
CN303623305S (ru)
CN303617638S (ru)
CN303611362S (ru)
CN303603675S (ru)
CN303586598S (ru)
CN303584934S (ru)
CN303536736S (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201111